An open-label study of CK-3773274 for patients with HCM

• Research type

  Research Study

• Full title

  An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM).

• IRAS ID

  1005788

• Contact name

  Cytokinetics MD

• Contact email

  medicalaffairs@cytokinetics.com

• Sponsor organisation

  Cytokinetics, Inc.

• Eudract number

  2020-003571-17

• Clinicaltrials.gov Identifier

  NCT04848506

• Research summary

  Participants in this study would have completed a previous study investigating the research medicine, CK-3773274. The purpose of this study is to determine the safety and long-term effects of CK- 3773274, and to learn how well it is tolerated at different, increasing dose levels in participants with HCM. The study will also measure the amount of CK-3773274 in patient's blood (PK – pharmacokinetics) at various times, its effect on the heart as seen by echocardiogram (PD – pharmacodynamics), and its effect on various HCM symptoms.

• REC name

  South Central - Hampshire A Research Ethics Committee

• REC reference

  22/SC/0327

• Date of REC Opinion

  16 Nov 2022

• REC opinion

  Further Information Favourable Opinion